Edition:
India

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

15.78EUR
1:42pm IST
Change (% chg)

€0.17 (+1.09%)
Prev Close
€15.61
Open
€15.50
Day's High
€15.99
Day's Low
€15.50
Volume
98,552
Avg. Vol
304,552
52-wk High
€24.50
52-wk Low
€13.35

About

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect... (more)

Overall

Beta: 1.34
Market Cap(Mil.): €635.67
Shares Outstanding(Mil.): 38.83
Dividend: --
Yield (%): --

Financials

BRIEF-Genfit Presents Additional Data from Positive Phase 2 Clinical Trial Of Elafibranor

* SAID ON SATURDAY FURTHER ANALYSIS SHOWS SIGNIFICANT IMPROVEMENTS IN PBC CHOLESTATIC MARKERS AND REDUCTION ON IMMUNO/INFLAMMATION MARKERS

15 Apr 2019

BRIEF-Genfit Raises Circa $155.4 Million Gross In Nasdaq Offering

* ANNOUNCED ON THURSDAY EXERCISE IN FULL OF THE OPTION GRANTED TO THE UNDERWRITERS OF ITS GLOBAL OFFERING AND NASDAQ GLOBAL SELECT MARKET LISTING TO PURCHASE UP TO 997,500 ADDITIONAL ADSS

29 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates